How Do GLP-1 Medications Help Type 2 Diabetes?

Last reviewed: June 16, 2026

Last updated: June 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications help type 2 diabetes by doing what the body's own glucagon-like peptide-1 hormone does, only for far longer. According to the Ozempic prescribing information, semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion — both in a glucose-dependent manner. It also produces a minor delay in early postprandial gastric emptying, which slows the rate at which glucose from a meal appears in the circulation. The downstream result is lower fasting and after-meal glucose, and in the large outcome trials, measurable reductions in cardiovascular and kidney events.

What "Glucose-Dependent" Means, and Why It Matters

That phrase is the single most important detail in the mechanism. Native GLP-1 is an incretin hormone released from the gut in response to food, and the insulin response it triggers scales with how much glucose is actually present. When blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. When glucose is not elevated, the signal largely stands down.

This is why GLP-1 receptor agonists behave differently from older agents that drive insulin release regardless of glucose level. The Ozempic label notes that patients receiving it in combination with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia including severe hypoglycemia, and that reducing the dose of the concomitant medication may be necessary. In that scenario the hypoglycemia risk is contributed largely by the partner drug.

The long duration of action is engineered separately from the mechanism. The label attributes semaglutide's half-life of approximately one week to albumin binding, which decreases renal clearance and protects the peptide from metabolic degradation, together with a structural modification that stabilizes it against the DPP-4 enzyme.

What the Glycemic Numbers Actually Look Like

In a 30-week double-blind monotherapy trial of 388 adults with type 2 diabetes inadequately controlled with diet and exercise, the label reports HbA1c changes of −1.4% and −1.6% for the two semaglutide dosages studied versus −0.1% for placebo, from mean baselines near 8.1%. Seventy-three percent and 70% of those treatment groups reached an HbA1c below 7%, against 28% on placebo.

Against an active comparator the margin narrows but persists. In a 30-week trial versus insulin glargine in patients already taking metformin or metformin with a sulfonylurea, HbA1c fell 1.2% and 1.5% on the two semaglutide dosages versus 0.9% on glargine, and 55% and 66% of patients reached below 7% versus 40%.

Pharmacodynamic data in the same label quantify the day-to-day effect. After 12 weeks of treatment at steady state, patients with type 2 diabetes showed reductions versus placebo of 29 mg/dL for fasting glucose, 74 mg/dL for two-hour postprandial glucose, and 30 mg/dL for mean 24-hour glucose concentration.

Weight Change Travels With It — But That Is Not the Indication

Body weight fell in those same diabetes trials. Compared with sitagliptin over 56 weeks, mean changes from baseline were −4.2 kg and −5.5 kg versus −1.7 kg. Compared with insulin glargine over 30 weeks, mean changes were −3.2 kg and −4.7 kg while the glargine arm gained 0.9 kg.

Those are secondary observations inside programs designed around glycemic endpoints. Ozempic's approved indications are glycemic control in adults with type 2 diabetes, reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no weight-management indication in that label and no BMI criterion anywhere in it. Wegovy is the semaglutide product approved for weight reduction.

The Cardiovascular and Kidney Evidence

SUSTAIN 6 was a multi-center, multi-national, placebo-controlled, double-blind cardiovascular outcomes trial in 3,297 patients with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease, followed for a minimum observation time of two years. The estimated hazard ratio for time to first major adverse cardiovascular event was 0.74 (95% CI 0.58 to 0.95). The trial was published in the New England Journal of Medicine in 2016.

The kidney evidence comes from FLOW, in which 3,533 patients with type 2 diabetes and chronic kidney disease were randomized and followed for a median of 41 months. Mean baseline eGFR was 47 mL/min/1.73m², and median baseline urine albumin-to-creatinine ratio was 568 mg/g. Semaglutide was superior to placebo on the composite of sustained eGFR decline of at least 50%, sustained eGFR below 15, chronic renal replacement therapy, renal death or cardiovascular death, with a hazard ratio of 0.76 (95% CI 0.66 to 0.88). All-cause death carried a hazard ratio of 0.80.

The label adds two honest caveats. The treatment benefit on the primary composite endpoint was not evident in patients already taking an SGLT2 inhibitor at baseline, though there were few events in that subgroup. And the mechanism of the kidney-related risk reduction has not been established.

The Risks the Label Requires Prescribers to Weigh

Ozempic carries a boxed warning for risk of thyroid C-cell tumors. In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors at clinically relevant exposures; whether it does so in humans has not been determined. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2, and in patients with a serious hypersensitivity reaction to semaglutide or the product's excipients.

The warnings section covers acute pancreatitis, diabetic retinopathy complications, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. The most common adverse reactions reported in at least 5% of treated patients are nausea, vomiting, diarrhea, abdominal pain and constipation.

An Adjunct, Not a Replacement

The indication language is precise: an adjunct to diet and exercise. GLP-1 therapy does not displace the rest of diabetes care — metformin, blood pressure and lipid management, glucose monitoring, retinal and kidney surveillance. It is layered onto that foundation, and the outcome trials that produced the numbers above were all run on top of standard of care.

One reassuring finding sits in the label: efficacy was not impacted by age, gender, race, ethnicity, baseline BMI, baseline body weight, diabetes duration, or level of renal function impairment. What varies most between individuals is tolerability and the interaction with the rest of a person's medication list, which is exactly the territory of a prescriber rather than an article.

Where Compounded Semaglutide Fits

Compounded semaglutide is a different regulatory category from the approved brands. It is not an FDA-approved finished product, the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Ozempic or Wegovy, because no approved generic of either exists.

The FDA's period of enforcement discretion for compounded semaglutide closed in 2025, which reshaped how compounded products may lawfully be prepared. PlexusDx dispenses exclusively through licensed 503A compounding pharmacies, and any decision about whether a compounded or an approved brand product is appropriate belongs to the prescriber who has evaluated you.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How do GLP-1 medications lower blood sugar?

According to the Ozempic prescribing information, semaglutide activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, so the insulin response scales with how much glucose is actually present. The mechanism also involves a minor delay in early postprandial gastric emptying, which slows the rate at which meal-derived glucose enters the circulation.

Do GLP-1 medications cause low blood sugar?

Because the insulin response is glucose-dependent, the risk on its own is limited. The label states that patients receiving Ozempic in combination with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia including severe hypoglycemia, and that a dose reduction of the concomitant medication may be necessary. That evaluation belongs to your prescriber.

How much does HbA1c drop on semaglutide?

In a 30-week monotherapy trial of 388 adults reported in the label, HbA1c fell 1.4% and 1.6% on the two dosages studied versus 0.1% on placebo, from mean baselines near 8.1%, with 73% and 70% of patients reaching below 7% versus 28% on placebo. Individual results vary, and the label notes efficacy was not affected by age, sex, race, baseline BMI or diabetes duration.

Does Ozempic protect the heart and kidneys?

It carries indications for both in type 2 diabetes. In SUSTAIN 6, involving 3,297 patients with established cardiovascular disease, the hazard ratio for time to first major adverse cardiovascular event was 0.74. In FLOW, involving 3,533 patients with chronic kidney disease followed a median of 41 months, the hazard ratio for the primary kidney composite endpoint was 0.76. The mechanism of kidney protection has not been established.

Is Ozempic approved for weight loss in people with diabetes?

No. Ozempic's three approved indications all concern type 2 diabetes: glycemic control, cardiovascular risk reduction in established cardiovascular disease, and cardiorenal risk reduction in chronic kidney disease. Weight reduction was observed as a secondary outcome across those trials, but the label contains no weight-management indication and no BMI criterion. Wegovy is the semaglutide product approved for weight reduction.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.